Session Details

Morning Session 4 - Meet the Experts: Virus-Specific T Cells
Sunday, September 15, 2019 07:00 AM - 08:30 AM 
Ballroom A
Join us for our last Morning Mental Workout to get your juices flowing for the rest of the day. Lynn O’Donnell, PhD – Director of the Cell Therapy Laboratory at The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, OH – will facilitate a lively discussion of topics related to technical, operational and regulatory challenges and controversies, professional development and perhaps topics like workplace politics and work-life balance with three internationally recognized experts in pre-clinical, translational development and clinical research of engineered virus-specific T cells (VSTs). Audience members will also have the opportunity to submit questions before and during the session using the Slido app, microphone and/or a loud voice. The goal is to be able to interact with and learn from these experts in a casual setting. Because of the rapidly growing interest in the topic of VSTs and vast experience of these experts, each will present a brief 10 minute overview of their work and career path before beginning separate, break-out Q&A discussions. We have added an additional 30 minutes to this Workout to allow for the full benefit and adequate time for attendees to hear from each of the three experts.


Lynn O'Donnell, PhD, Ohio State University, James Cancer Hospital Columbus, USA


Virus specific T cell therapies- broadening applicability beyond CMV and EBV
Catherine Bollard, MBChB, MD, Children’s National Medical Center, USA
Learning objectives:
•      Understanding the breadth of T cell therapies targeting viruses
•      Understanding strategies for generating a VST “bank” for third party use
•      Discuss the use of naïve donor sources for VST products

John Barrett, MDGeorge Washington University Hospital, USA
Learning objectives:
•      The diversity of human polyomaviruses and the diseases they cause
•      The normal immune response to the viruses and the effect of immune deficiency on viral reactivation
•      Cell therapies to treat BK Virus, JC virus and Merkel Cell Virus.

Third Party Virus Specific T cells (VSTs): Cincinnati Experience
Michael Grimley, MD, Cincinnati Children's Hospital Medical Center, USA
Learning objectives:
•      Discuss the manufacturing process for Viral Specific T cells (VSTs)
•      Clinical results from the use of third party VSTs
•      Indications for the use of third party VSTs

Lynn O'Donnell PhD
Associate Professor/Director of Cellular Therapy Laboratory
Ohio State University, James Cancer Hospital Columbus

John Barrett MD
Director, Stem Cell Transplant and Cell Therapy Program
George Washington Cancer Center

Catherine Bollard MD, FRACP, FRCPA
Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine
Children's National Medical Center

Michael Grimley MD
Cincinnati Children's Hospital Medical Center